Blinatumomab bi-specific T-cell engager (BiTE) drug. Targets CD19 and CD3; indicated for the treatment of acute lymphoblastic #186833169
Description
Blinatumomab bi-specific T-cell engager (BiTE) drug. Targets CD19 and CD3; indicated for the treatment of acute lymphoblastic leukemia (ALL). Generic name and stylized antibody representation